Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

What this Trial Is About

Researchers are studying the effectiveness of three blood biomarkers—the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)—to improve the diagnosis and monitoring of preeclampsia, a serious pregnancy complication marked by high blood pressure and organ damage. This condition affects 2-8% of pregnancies worldwide and is linked to placental problems and abnormal blood vessel growth. Current clinical indicators are limited, so these biomarkers may offer better early detection and help track treatment responses. The study includes three groups: pregnant women with preeclampsia not yet on antihypertensive treatment, pregnant women with preeclampsia receiving standard antihypertensive therapy, and healthy pregnant women as controls. Blood samples are collected at diagnosis or during routine care between 20 and 36 weeks of pregnancy. Samples are processed and stored for detailed biomarker analysis, including sFlt-1, PlGF, soluble endoglin, and osteoprotegerin levels. Participants will be monitored through blood testing at enrollment to measure the key biomarkers. Clinical data and treatment details are also recorded for analysis. The study aims to evaluate serum concentrations of these biomarkers and their ratios to better understand their role in diagnosing and managing preeclampsia. This observational study lasts from enrollment through routine prenatal care, with no additional interventions beyond standard clinical management.

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia